Atara Biotherapeutics (ATRA) to Release Earnings on Tuesday

Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Atara Biotherapeutics to post earnings of ($3.77) per share for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The company had revenue of $28.64 million during the quarter, compared to the consensus estimate of $48.30 million. On average, analysts expect Atara Biotherapeutics to post $-12 EPS for the current fiscal year and $-17 EPS for the next fiscal year.

Atara Biotherapeutics Stock Up 1.2 %

Shares of Atara Biotherapeutics stock traded up $0.12 on Wednesday, hitting $10.40. The stock had a trading volume of 6,781 shares, compared to its average volume of 104,758. Atara Biotherapeutics has a one year low of $4.96 and a one year high of $39.50. The stock’s 50-day simple moving average is $8.41 and its two-hundred day simple moving average is $10.51. The stock has a market cap of $51.12 million, a price-to-earnings ratio of -0.26 and a beta of 0.50.

Wall Street Analysts Forecast Growth

ATRA has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $13.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 13th. The Goldman Sachs Group dropped their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price objective for the stock from $25.00 to $18.00 in a report on Friday, August 16th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.00.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.